StockNews.com Begins Coverage on IRIDEX (NASDAQ:IRIX)

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Thursday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Up 2.6 %

IRIX stock opened at $1.55 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. The firm has a market cap of $25.79 million, a PE ratio of -2.31 and a beta of 0.84. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65. The firm has a 50 day simple moving average of $1.67 and a 200 day simple moving average of $1.74.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The firm had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same period in the previous year, the business posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.